Pirags V.
724
Coauthors
11
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2008 | 1 |
| 2012 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Medicina interna | 10 |
| Diabetes | 7 |
| Enfermedad cardiovascular | 4 |
| Cognición | 2 |
| Medicamento | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 10 |
| Farmacología y terapéutica | 7 |
| Medicina y salud | 5 |
| Fisiología humana | 5 |
| Problemas sociales y servicios a grupos | 1 |
| Ginecología, obstetricia, pediatría, geriatría | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 11 |
| Google Scholar | 6 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Gerstein H.C. | 11 |
| Probstfield J.L. | 11 |
| PATRICIO LOPEZ -JARAMILLO | 11 |
| Rydén L.E. | 11 |
| Dagenais G.R. | 10 |
| Riddle M.C. | 10 |
| Keltai M. | 10 |
| Hanefeld M. | 8 |
| Lanas F.T. | 8 |
| Hâncu N. | 8 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
ArticleAbstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 rPalabras claves:Autores:Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.Fuentes:googlescopusTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
ArticleAbstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) doublePalabras claves:Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 DiabetesAutores:Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusNovel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
ArticleAbstract: Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationshiPalabras claves:cardiovascular events, cognitive impairment, Composite outcome, death, Geometric mean, MACE, risk factor, strokeAutores:Angelyn Bethel M., Basile J.N., Cardona-Munoz E.G., Conget I., Cukierman-Yaffee T., Dagenais G.R., Franek E., Gerstein H.C., Hall S., Hâncu N., Jansky P., Lakshmanan M., Lanas F., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Ramasundarahettige C., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusEffect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigatePalabras claves:Autores:Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:googlescopusDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
ArticleAbstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucaPalabras claves:antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonistAutores:Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:scopus